ミズーリ州における小細胞肺がんの臨床試験
ミズーリ州内の拠点で、小細胞肺がんに関する17件の研究が参加者を募集しています。
ミズーリ州内の都市
公式研究テキスト（英語）
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Missouri Cancer Associates /ID# 278299, Columbia
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07155174DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- HCA MidAmerica Division, Inc., Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07472517A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Missouri Cancer Associates, Columbia
- Mercy South, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07218146Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Washington University School of Medicine, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT06712355Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- WA Uni School Of Med, St Louis
被験者募集中第1/2相
18歳〜100歳 · 全性別 · 2026/08/27更新 · NCT06726148A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- Washington University Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07488923Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
- Washington University School of Medicine, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/12更新 · NCT07155200A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Mercy Clinic Oncology and Hematology Sindelar Cancer Center, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/06更新 · NCT06203210DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07545954A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- MidAmerica Cancer Care, Kansas City
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT06131840A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Washington University School of Medicine (Siteman Cancer Center), St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT05652686A Study of LY4175408 in Participants With Advanced Cancer
- Washington University, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Siteman Cancer Center, Washington University, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/08更新 · NCT05363280Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center - Lee's Summit, Lee's Summit
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/30更新 · NCT06769126Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/09更新 · NCT054904727T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
- University of Missouri, Columbia
被験者募集中観察研究
18歳以上 · 全性別 · 2025/12/02更新 · NCT07175077ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。